Chimerix signs antiviral deal with Merck; FDA approves interactive insulin pump;

> Chimerix, which uses its lipid-antiviral conjugate technology to improve drug delivery, has signed a deal with Merck ($MRK), giving it access to the HIV antiviral CMX157. Article

> The FDA has approved Roche's ($RHHBY) Accu-Chek Combo interactive insulin pump system. Article

> A hyaluronic acid drug delivery system, delivering 5-fluorouracil over several weeks, could reduce scarring after glaucoma surgery. The study has been shortlisted for a Best Clinical Research Oral Presentation Award at the second SingHealth Duke-NUS Scientific Congress. Article

> NeuroDerm, a transdermal drug delivery developer, is raising $15 million. Article

> Opko Health has signed a research and license agreement for a topically active formulation of the anti-VEGF antibody, ranibizumab, to treat diabetic macular edema. Article

> Airway-targeted PLGA nanoparticles could deliver drugs in obstructive lung disease. Abstract

And Finally… An RNAi drug delivery company secures $1.6M for endosomal escape technology. Article